

Format for disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Krebs Biochemicals and Industries Limited		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the Acquirer	Ipca Laboratories Limited		
Whether the acquirer belongs to Promoter / Promoter Group	Yes (having made Public Announcement of open offer for acquiring shares in TC under Regulation 3(1) and 4)		
Name(s) of the Stock Exchange(s) where the shares of TC are listed	BSE Limited & National Stock Exchange of India Ltd.		
Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
Before the acquisition under consideration, holding of acquirer along with PACs of:			
a. Shares carrying voting rights	18,00,000	18.92% [#]	18.92% [#]
b. Shares in the nature of encumbrance (pledge/lien/non-disposal undertaking/others)	The above shares carry non-disposal undertaking for specified period		
c. Voting rights (VR) otherwise than by equity shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	Nil	Nil	Nil
e. Total (a+b+c+d)	18,00,000	18.92%	18.92%
Details of Acquisition			
a. Shares carrying voting rights acquired	23,00,000	18.53% ^{##}	18.53% ^{##}
b. VRs acquired otherwise than by equity shares	Nil	Nil	Nil
c. Warrants / Convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) acquired	Nil	Nil	Nil
d. Shares encumbered /invoked/released by the acquirer	The above shares allotted are subject to non-disposal undertaking for specified period		
e. Total (a+b+c+d)	23,00,000	18.53%	18.53%

Details of the acquisition as follows	Number	% w.r.t total share / voting capital wherever applicable (*)	% w.r.t. total diluted share / voting capital of the TC (**)
After the acquisition, holding of			
a. Shares carrying voting rights	41,00,000	33.03% ^{##}	33.03% ^{##}
b. Shares encumbered with the acquirer	The above shares carry non-disposal undertaking for specified period		
c. VRs otherwise than by shares	Nil	Nil	Nil
d. Warrants / convertible securities / any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition	Nil	Nil	Nil
e. Total (a+b+c+d)	41,00,000	33.03%	33.03%
Mode of acquisition (eg. Open market / off-market/public issue/rights issue/preferential allotment/inter-se transfer etc.)	Preferential Allotment		
Date of acquisition of shares/VR or date of receipt of intimation of allotment of shares, whichever is applicable	May 9, 2015		
Equity share capital/total voting capital of the TC before the said acquisition	95,14,286	100%	100%
Equity share capital /total voting capital of the TC after the said acquisition	1,24,14,286	100%	100%
Total diluted share/voting capital of the TC after the said acquisition	1,24,14,286	100%	100%

(*) Total share capital/voting capital to be taken as per the latest filing done by the Company to the Stock Exchange under Clause 35 of the Listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

On pre-preferential allotment Equity Capital of 95,14,286 Equity Shares

On post-preferential allotment Equity Capital of 1,24,14,286 Equity Shares

Signature of the acquirer / Authorised Signatory:

For Ipca Laboratories Ltd.

Harish P. Kamath
Company Secretary

Place: Mumbai

Date: May 11, 2015

